Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid.
Department of Endocrinology and Diabetes and Metabolism (P.M.), 251 Hellenic Air Force and VA General Hospital, 11525 Athens, Greece; School of Medicine (S.A.P.), Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece; Department of Endocrinology (A.D.A.), 424 General Military Hospital, 56429 Thessaloniki, Greece.
Polyzois
P
Makras
Department of Endocrinology and Diabetes and Metabolism (P.M.), 251 Hellenic Air Force and VA General Hospital, 11525 Athens, Greece; School of Medicine (S.A.P.), Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece; Department of Endocrinology (A.D.A.), 424 General Military Hospital, 56429 Thessaloniki, Greece.
Stergios A
SA
Polyzos
Department of Endocrinology and Diabetes and Metabolism (P.M.), 251 Hellenic Air Force and VA General Hospital, 11525 Athens, Greece; School of Medicine (S.A.P.), Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece; Department of Endocrinology (A.D.A.), 424 General Military Hospital, 56429 Thessaloniki, Greece.
Athanasios D
AD
Anastasilakis
D015519:Bone Density; D050071:Bone Density Conservation Agents; D000069448:Denosumab; D004164:Diphosphonates; D006801:Humans; D007093:Imidazoles; D008903:Minerals; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D008903:Minerals; D000069448:Denosumab; D000077211:Zoledronic Acid